Professional Documents
Culture Documents
The marketing practices of pharmaceutical companies raise doubts in the minds of many, from
patients to policy leaders and other health care stakeholders.In recent times, actions have been
taken to bring greater transparency to the relationships the industry has with health care providers,
including the Physician Payments Sunshine Act.This lead us to ask:
How much do stakeholders really want to know about the interactions
between companies and health care providers? Even more, we wanted
to know: Is there any benefit or only risk in these interactions?
APCO Insight conducted a poll to explore if collaboration between
these interested parties can yield positive benefits, or not.
INTEREST
90%
86%
60%
Opinion
Leaders
Policy
Leaders
Payers
59%
Health Care
Providers
95%
86%
Females
ACTION
While interest is high, fewer are likely to go online or ask their doctor directly
about physician relationships with pharmaceutical companies.
How likely are you to go online to see if
your doctor is receiving payments?
Percent Very/Somewhat Likely
85%
75%
66%
48%
Opinion
Leaders
Policy
Leaders
Payers
42%
41%
25%
Health Care
Providers
Opinion
Leaders
Policy
Leaders
Payers
16%
Health Care
Providers
IMPACT
Communicating with other medical professionals to share experiences and learn about best practices:
77%
Conducting research studies or clinical trials to develop new medicines or medical devices:
76%
74%
Consulting with companies on specific projects that require specialized medical expertise:
73%
61%
APCO Insight conducted 1,525 interviews, including Health Care Opinion Leaders (n=775) Health
Care Providers (n=621), Policy Leaders (n=83) and Payers (n=46) between October 24, 2014 and
January 13, 2015. Interviews were conducted online or over the telephone.
For more information, please visit rorindicator.com or contact Chrystine Zacherau at
czacherau@apcoworldwide.com